ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SION vs TRDA // OPERATING MARGIN

Sionna Therapeutics Inc. (NASDAQ) VS. Entrada Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SION 1 — TRDA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SION VS. TRDA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SION TRDA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.30% -35.00% +6.70 SION /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 32.0 49.6 -17.60 TRDA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $168.6M $199.0M -$30.3M TRDA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SION REV TRDA REV SION GROSS % TRDA GROSS % SION FCF TRDA FCF
FY 2025 $249.1M $25.4M — — -$66.7M -$129.6M
FY 2024 $197.6M $210.8M — — -$52.8M -$44.7M
FY 2023 — $129.0M — — — $139.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SION // BETA —
TRDA // BETA —